Literature DB >> 18366449

Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.

S Grabar1, E Lanoy, C Allavena, M Mary-Krause, M Bentata, P Fischer, A Mahamat, C Rabaud, D Costagliola.   

Abstract

OBJECTIVES: To analyse the impact of combined antiretroviral treatment (cART) on survival with AIDS, according to the nature of the first AIDS-defining clinical illness (ADI); to examine trends in AIDS-defining causes (ADC) and non-AIDS-defining causes (non-ADC) of death.
METHODS: From the French Hospital Database on HIV, we studied trends in the nature of the first ADI and subsequent survival in France during three calendar periods: the pre-cART period (1993-1995; 8027 patients), the early cART period (1998-2000; 3504 patients) and the late cART period (2001-2003; 2936 patients).
RESULTS: The three most frequent initial ADIs were Pneumocystis carinii (jirovecii) pneumonia (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre-cART period. In the late cART period, the most frequent ADIs were tuberculosis (22.7%), PCP (19.1%) and oesophageal candidiasis (16.2%). The risk of death after a first ADI fell significantly after the arrival of cART. Lower declines were observed for progressive multifocal leukoencephalopathy, lymphoma and Mycobacterium avium complex infection. After an ADI, the 3-year risk of death from an ADC fell fivefold between the pre-cART and late cART periods (39%vs. 8%), and fell twofold for non-ADCs (17%vs. 9%).
CONCLUSIONS: The relative frequencies of initial ADI have changed since the advent of cART. Tuberculosis is now the most frequent initial ADI in France; this is probably the result of the increasing proportion of migrants from sub-Saharan Africa. After a first ADI, cART has a major impact on ADCs and a smaller impact on deaths from other causes. The risk of death from AIDS and from other causes is now similar.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18366449     DOI: 10.1111/j.1468-1293.2008.00554.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  21 in total

1.  Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Authors:  Katherine Huppler Hullsiek; Birgit Grund
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

2.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.

Authors:  Jacqueline Neuhaus; Brian Angus; Justyna D Kowalska; Alberto La Rosa; Jim Sampson; Deborah Wentworth; Amanda Mocroft
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

3.  Opportunistic Infections and Mortality: Still Room for Improvement.

Authors:  Henry Masur; Sarah W Read
Journal:  J Infect Dis       Date:  2015-06-03       Impact factor: 5.226

4.  A structured approach to recording AIDS-defining illnesses in Kenya: A SNOMED CT based solution.

Authors:  Tom Oluoch; Nicolette de Keizer; Patrick Langat; Irene Alaska; Kenneth Ochieng; Nicky Okeyo; Daniel Kwaro; Ronald Cornet
Journal:  J Biomed Inform       Date:  2015-07-13       Impact factor: 6.317

5.  Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus.

Authors:  Bethany A O'Hara; Gretchen V Gee; Walter J Atwood; Sheila A Haley
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 6.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

7.  Infrequent detection of Pneumocystis jirovecii by PCR in oral wash specimens from TB patients with or without HIV and healthy contacts in Tanzania.

Authors:  Lotte Jensen; Andreas V Jensen; George Praygod; Jeremiah Kidola; Daniel Faurholt-Jepsen; John Changalucha; Nyagosya Range; Henrik Friis; Jannik Helweg-Larsen; Jorgen S Jensen; Aase B Andersen
Journal:  BMC Infect Dis       Date:  2010-05-28       Impact factor: 3.090

8.  Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Authors:  Sara Lodi; Marguerite Guiguet; Dominique Costagliola; Martin Fisher; Andrea de Luca; Kholoud Porter
Journal:  J Natl Cancer Inst       Date:  2010-05-04       Impact factor: 13.506

9.  Usefulness of stereotactic biopsy and neuroimaging in management of HIV-1 Clade C associated focal brain lesions with special focus on cerebral toxoplasmosis.

Authors:  C Shyam babu; P Satishchandra; A Mahadevan; V Pillai Shibu; S Ravishankar; N Sidappa; R Udaykumar; V Ravi; S K Shankar
Journal:  Clin Neurol Neurosurg       Date:  2012-11-12       Impact factor: 1.876

10.  Evidence for limited genetic compartmentalization of HIV-1 between lung and blood.

Authors:  Laura Heath; Alan Fox; Jan McClure; Kurt Diem; Angélique B van 't Wout; Hong Zhao; David R Park; Jeffrey T Schouten; Homer L Twigg; Lawrence Corey; James I Mullins; John E Mittler
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.